Sentinel Lymph Node in Early-Stage Endometrium Cancer

Launched by ISTANBUL UNIVERSITY · Dec 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new method to detect sentinel lymph nodes (SLNs) in women with early-stage endometrial cancer, which is a type of cancer that starts in the lining of the uterus. The researchers want to find out if using two different tracers injected at two locations will help doctors find these lymph nodes more effectively than the standard method, which uses just one tracer injected at one site. By improving detection, doctors hope to better understand how far the cancer has spread, which is crucial for planning the best treatment.

To participate in this study, women aged 65 to 74 who have been diagnosed with early-stage endometrial cancer may be eligible. They need to give written consent to join the trial. However, individuals who have had allergies to common medications, certain medical conditions, or signs of more advanced cancer will not be included. If you join the trial, you can expect to undergo additional tests to help with the detection of lymph nodes, which may provide important information for your treatment plan.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Must have preoperative histologic diagnosis of endometrial carcinoma
• • 2. Must be in early stage ( stage1 and 2) endometrial carcinoma radiologically and clinically
• • 3. Must have written informed consent
• Exclusion Criteria:
• • 1. Possible allergic reaction to commonly used drugs
• • 2. Medical or surgical contraindications for comphrensive staging
• • 3. Preoperative or intraoperative findings of advanced endometrial cancer